BMRN: third_quarter 2026 lobbying report

{"url":"https://lda.gov/api/v1/filings/e2f8c0b5-d05d-4125-8522-f6920b2dcae0/","filing_uuid":"e2f8c0b5-d05d-4125-8522-f6920b2dcae0","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/e2f8c0b5-d05d-4125-8522-f6920b2dcae0/print/","filing_document_content_type":"text/html","income":null,"expenses":"200000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Jason D. Kaune, Attorney & Agent for Filer","dt_posted":"2026-10-20T16:44:39-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"770 Lindaro Street","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"San Rafael","registrant_state":"CA","registrant_zip":"94901","registrant":{"id":401049958,"url":"https://lda.gov/api/v1/registrants/401049958/","house_registrant_id":42322,"name":"BIOMARIN PHARMACEUTICAL INC.","description":"Develops and commercializes biopharmaceuticals.","address_1":"770 Lindaro Street","address_2":null,"address_3":null,"address_4":null,"city":"San Rafael","state":"CA","state_display":"California","zip":"94901","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JASON KAUNE","contact_telephone":"+1 415-389-6800","dt_updated":"2026-07-31T17:25:51.428415-04:00"},"client":{"id":197314,"url":"https://lda.gov/api/v1/clients/197314/","client_id":12,"name":"BIOMARIN PHARMACEUTICAL INC.","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2013-04-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"H.R.10571: SURGE TO SAVE NEWBORNS ACT; PROVISIONS RELATED TO NEWBORN SCREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS REGARDING GENETIC SCREENING AND TESTING","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":154578,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"MAYNE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) FOREIGN REFERENCE PRICING GENERAL DISCUSSIONS REGARDING UTILIZATION MANAGEMENT","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":154578,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"MAYNE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAR","general_issue_code_display":"Tariff (miscellaneous tariff bills)","description":"GENERAL DISCUSSIONS REGARDING TARIFFS","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":154578,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"MAYNE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"H.R.10359: PRIORITY FOR PEDIATRIC CURES ACT; PROVISIONS RELATED TO REMOVAL OF RARE PEDIATRIC PRIORITY REVIEW VOUCHERS SUNSET GENERAL DISCUSSIONS REGARDING CLINICAL TRIALS","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":154578,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"MAYNE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"H.R. 1414: CAMERON'S LAW; ALL PROVISIONS","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":154578,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"MAYNE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"DISCUSSIONS REGARDING INTELLECTUAL PROPERTY AND U.S. INTERNATIONAL TRADE COMMISSION EXCLUSION ORDER","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":154578,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"MAYNE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}